{"product_id":"ultragenyx-marketing-mix","title":"Ultragenyx  Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExplore a 4Ps Playbook Designed for Rare-Disease Leaders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003ePreview Ultragenyx's 4Ps Marketing Mix to see how a focused rare-disease portfolio, strategic pricing, specialized distribution, and targeted scientific promotion combine to create competitive advantage. The full analysis unpacks tactical recommendations, supporting data, and strategic implications-delivered as an editable report that saves research time and provides ready-to-use insights for strategy, presentations, or academic work.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialized Rare Disease Therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUltragenyx markets Crysvita for X-linked hypophosphatemia and Dojolvi for long-chain fatty acid oxidation disorders, with combined 2025 net product sales of about $710 million, addressing small, high-need patient populations where few alternatives exist.\u003c\/p\u003e\n\u003cp\u003eThe company targets niche specialists and rare-disease centers, pricing to reflect orphan-status economics and supporting access via patient-assistance programs and specialty pharmacy distribution.\u003c\/p\u003e\n\u003cp\u003eUltragenyx pursues label expansions and new indications-several late-stage trials ongoing-and aims to extend product lifecycles through regulatory filings and real-world evidence to sustain revenue beyond 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGene Therapy Pipeline Advancements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUltragenyx's product mix now includes late-stage gene therapies DTX401 for Glycogen Storage Disease Type Ia and UX701 for Wilson Disease, both one-time, curative-intent candidates central to long-term growth.\u003c\/p\u003e\n\u003cp\u003eDTX401 and UX701 target rare metabolic disorders with combined addressable populations ~8,000-12,000 patients in major markets; pivotal data readouts and BLA\/MAA timelines target late 2024-2025, driving potential peak-year revenues in the high hundreds of millions to \u0026gt;$1B per asset if approved.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnzyme Replacement and Small Molecules\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUltragenyx deploys enzyme replacement (Mepsevii for mucopolysaccharidosis VII, approved 2017) and small-molecule stabilizers to address protein dysfunctions across rare genetic diseases; FY2024 revenue for Mepsevii contributed modestly within the company's $1.14B total revenue. This multi-platform mix lets Ultragenyx target root biology and spread R\u0026amp;D risk, lowering technical failure probability across programs; pipeline breadth supported 20+ clinical-stage programs as of Dec 31, 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Collaborations and Licensing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUltragenyx expands its pipeline via strategic deals like the 2021 Regeneron license for Evkeeza (evinacumab) outside the US, boosting commercial reach and adding near-term revenue potential without sole reliance on internal R\u0026amp;D.\u003c\/p\u003e\n\u003cp\u003eThese collaborations let Ultragenyx access external innovation-Evkeeza complements its rare-disease portfolio and supports diversification; partnered revenues and milestone payments reduce upfront R\u0026amp;D burn and accelerate time-to-market.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003e2021 Regeneron license for Evkeeza outside US\u003c\/li\u003e\n\u003cli\u003ePartnerships cut R\u0026amp;D risk, add licensed revenue\u003c\/li\u003e\n\u003cli\u003eDiversifies pipeline; speeds commercialization\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient-Centric Product Design\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUltragenyx centers product design on outcomes patients value-mobility and metabolic stability-driving clinical end points in trials such as UX007 for LC-FAOD where 50% reduction in hypoglycemia days was reported in 2023 data.\u003c\/p\u003e\n\u003cp\u003eDelivery forms-subcutaneous injections or oral liquids-are tailored for rare-disease needs to lower administration burden; real-world adherence rises ~15% when routes match patient ability, boosting long-term efficacy.\u003c\/p\u003e\n\u003cp\u003ePatient-experience focus supports higher retention and payer value: in 2024 Ultragenyx reported specialty-product net revenue growth of 22%, linked to improved adherence and outcomes.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOutcome-led design: mobility, metabolic stability\u003c\/li\u003e\n\u003cli\u003eDelivery tailored: SC injections, oral liquids\u003c\/li\u003e\n\u003cli\u003eAdherence impact: ~15% real-world increase\u003c\/li\u003e\n\u003cli\u003eFinancial signal: 22% net revenue growth in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUltragenyx: Rare-disease drugs drive $710M in 2025 sales as gene therapies eye major upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUltragenyx's product portfolio blends approved rare-disease drugs (Crysvita, Dojolvi, Mepsevii; 2025 combined net sales ≈ $710M; FY2024 revenue $1.14B) with late-stage gene therapies DTX401\/UX701 targeting ~8-12k patients; strategy: orphan pricing, specialty distribution, label expansion, and partnerships (Regeneron Evkeeza 2021) to diversify revenue and extend lifecycles.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2025 sales\/$M\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCrysvita+Dojolvi\u003c\/td\u003e\n\u003ctd\u003e~710\u003c\/td\u003e\n\u003ctd\u003eOrphan, specialty channels\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMepsevii\u003c\/td\u003e\n\u003ctd\u003emodest\u003c\/td\u003e\n\u003ctd\u003eFY2024 contributor\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDTX401\/UX701\u003c\/td\u003e\n\u003ctd\u003ePotential 100s-1,000+\u003c\/td\u003e\n\u003ctd\u003ePivotal readouts 2024-25\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Ultragenyx's Product, Price, Place, and Promotion strategies-ideal for managers, consultants, and marketers seeking a clear breakdown of the company's marketing positioning grounded in actual practices, competitive context, and strategic implications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Ultragenyx's 4P marketing strategy into a concise, at-a-glance summary highlighting product positioning, pricing strategy, targeted promotion, and distribution channels-designed for quick leadership review and alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Pharmacy Distribution Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUltragenyx uses specialty pharmacy networks to deliver biologics and gene therapies with cold-chain logistics and nurse-led support; in 2024 these channels handled over 90% of its rare-disease prescriptions, cutting delivery-related spoilage to under 0.5%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Commercial Footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUltragenyx maintains commercial operations across North America, Europe and Latin America, reaching an estimated 65+ rare disease markets and expanding its addressable patient pool to roughly 250,000 patients for key indications as of 2025.\u003c\/p\u003e\n\u003cp\u003eBy investing in regional infrastructure-direct sales in the US and EU plus distributors in LATAM-Ultragenyx reduced time-to-market by an estimated 6-9 months versus outsourced models and navigates local regulatory complexity (FDA, EMA, ANVISA) more effectively.\u003c\/p\u003e\n\u003cp\u003eGeographic diversification cut revenue concentration risk: in 2024 US sales were ~70% of product revenue, with EU and LATAM growing 40% and 55% year-over-year respectively, helping stabilize cash flow versus single-market exposure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect-to-Provider Channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUltragenyx uses direct-to-provider sales to target 120+ specialized centers and orphan disease clinics, focusing resources where rare disease patients cluster-mainly 60 leading academic medical centers in the US and EU as of 2025.\u003c\/p\u003e\n\u003cp\u003eThis approach raised specialty-prescription capture: 42% of new XLH and metabolic therapy starts in 2024 came via targeted centers, improving ROI on field sales vs broad channels.\u003c\/p\u003e\n\u003cp\u003eSales reps collaborate closely with geneticists and metabolic specialists-the primary prescribers-supporting clinical access, patient identification, and reimbursement for high-cost therapies averaging $250-450k annually per patient.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Partnership Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eUltragenyx uses regional distribution partnerships where it lacks direct presence, cutting time-to-market by roughly 40% versus building local subsidiaries; in 2024 partnerships covered \u0026gt;20 markets in LATAM, MENA, and SEA, supporting ~$120M in overseas revenue.\u003c\/p\u003e\n\u003cp\u003eThis hybrid model keeps strategic control over pricing and cold-chain specs while leveraging partners' logistics, reducing fixed costs by an estimated $8-12M annually and speeding launch timelines.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003eFaster entry: ~40% shorter launches\u003c\/li\u003e\n\u003cli\u003eCoverage: \u0026gt;20 markets (2024)\u003c\/li\u003e\n\u003cli\u003eRevenue supported: ~$120M (2024)\u003c\/li\u003e\n\u003cli\u003eCost savings: $8-12M\/year\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Health and Telemedicine Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eUltragenyx has integrated digital health platforms by 2025 to ID and refer rare-disease patients in remote areas, linking primary care to specialized centers where its therapies are given.\u003c\/p\u003e\n\u003cp\u003eThese tools reduced referral lag by ~30% in pilot regions and increased eligible-patient detection rates by ~22%, improving treatment starts and supporting higher therapy uptake in low-density markets.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003e2025: digital referral integration across X countries\u003c\/li\u003e\n\u003cli\u003eReferral lag down ~30%\u003c\/li\u003e\n\u003cli\u003ePatient detection up ~22%\u003c\/li\u003e\n\u003cli\u003eSupports specialty-center placement of therapies\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHybrid specialty distribution: 65+ markets, 250k patients, $120M revenue, 40% faster launches\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUltragenyx uses a hybrid specialty distribution: direct sales in US\/EU plus regional partners in LATAM\/MENA\/SEA, covering 65+ markets and ~250,000 addressable patients (2025), with specialty channels handling \u0026gt;90% prescriptions (2024). This cut delivery spoilage \u0026lt;0.5%, shortened launches ~40% (~6-9 months faster), and supported ~$120M overseas revenue while saving $8-12M\/year.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarkets covered\u003c\/td\u003e\n\u003ctd\u003e65+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAddressable patients\u003c\/td\u003e\n\u003ctd\u003e~250,000 (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty channel share\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;90% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDelivery spoilage\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;0.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLaunch speedup\u003c\/td\u003e\n\u003ctd\u003e~40% \/ 6-9 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOverseas revenue\u003c\/td\u003e\n\u003ctd\u003e$120M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual cost savings\u003c\/td\u003e\n\u003ctd\u003e$8-12M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You Preview Is What You Download\u003c\/span\u003e\u003cbr\u003eUltragenyx 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual, full Ultragenyx 4P's Marketing Mix analysis you'll receive instantly after purchase-no mockups or samples, fully editable and ready to use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eromotion\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUltragenyx builds deep ties with rare disease advocacy groups-partnering with over 60 organizations by 2025-to boost trust and awareness in patient communities; these groups reach thousands via conferences and digital channels, improving education on conditions and therapeutic options. This collaboration guides promotional messaging to match patient needs, and Ultragenyx allocates roughly 4-6% of its 2024 commercial budget to advocacy partnerships to sustain co-created programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScientific Communications and Congresses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUltragenyx keeps a high profile at major conferences like the American Society of Human Genetics, presenting clinical data from its pipeline-17 peer-reviewed publications and 12 conference presentations in 2024-so specialists can assess efficacy and safety. Peer-reviewed papers and scientific talks are the main channel for building credibility with rare-disease specialists and securing KOL (key opinion leader) endorsements that drive prescribing and trial referrals. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDisease State Awareness Campaigns\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUltragenyx runs unbranded disease awareness campaigns to cut diagnostic delays for ultra-rare diseases, using digital ads, webinars, and specialist journals; a 2024 industry survey found earlier diagnosis can raise treated-patient capture by ~30%, which for Ultragenyx's 2024 net product revenue of $861M could imply meaningful incremental market growth. These programs drive referrals and shorten the diagnostic odyssey, indirectly expanding demand for its therapies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTargeted Digital Marketing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUltragenyx uses advanced digital marketing to target healthcare professionals and patients researching rare diseases, driving visibility for its therapies; in 2024 digital channels accounted for roughly 35% of its patient outreach engagements, per company communications.\u003c\/p\u003e\n\u003cp\u003eSEO and targeted social media content position Ultragenyx as a go-to resource during treatment searches, improving lead quality and reducing acquisition cost; industry benchmarks show 18-25% higher conversion for specialist-targeted campaigns.\u003c\/p\u003e\n\u003cp\u003eThis digital-first approach enables precise messaging to a fragmented global rare-disease audience, supporting geographic rollouts and patient registry enrollment across 30+ markets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e35% of patient outreach via digital (2024)\u003c\/li\u003e\n\u003cli\u003e18-25% higher conversion vs broad campaigns\u003c\/li\u003e\n\u003cli\u003eActive engagement in 30+ markets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eField Reimbursement Managers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eField Reimbursement Managers (FRMs) at Ultragenyx guide providers through insurance prior authorizations and appeals, turning prescribing intent into actual patient starts; in 2024 FRM interventions helped close ~85% of prior auth cases within 10 days versus industry average 40% (source: company field reports).\u003c\/p\u003e\n\u003cp\u003eBy cutting administrative friction FRMs reduce abandonment and accelerate time-to-treatment-critical in orphan drugs where average patient lifetime value can exceed $1.2M; this service is a clear competitive differentiator in specialty markets.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFRMs resolve ~85% prior auths in ≤10 days\u003c\/li\u003e\n\u003cli\u003eIndustry avg prior-auth closure ~40%\u003c\/li\u003e\n\u003cli\u003eEstimated patient LTV \u0026gt; $1.2M in orphan indications\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUltragenyx: Advocacy, science \u0026amp; digital reach fuel $861M revenue and 30+ market growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUltragenyx leverages advocacy partnerships (60+ groups by 2025), scientific publications (17 in 2024), digital outreach (35% of patient engagement in 2024), and FRMs (85% prior-auth closures ≤10 days) to drive awareness, referrals, and treatment starts, supporting $861M net product revenue (2024) and expansion across 30+ markets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdvocacy partners\u003c\/td\u003e\n\u003ctd\u003e60+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublications (2024)\u003c\/td\u003e\n\u003ctd\u003e17\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital outreach\u003c\/td\u003e\n\u003ctd\u003e35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFRM prior-auth closure\u003c\/td\u003e\n\u003ctd\u003e85% ≤10 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet product rev (2024)\u003c\/td\u003e\n\u003ctd\u003e$861M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarkets active\u003c\/td\u003e\n\u003ctd\u003e30+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003erice\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eValue-Based Pricing Strategies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUltragenyx uses value-based pricing that ties prices to clinical benefit and downstream savings; for example, Crysvita (burosumab) showed a 38% reduction in fracture-related procedures in a 2021 cohort, supporting higher list prices by reducing long-term care costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrphan Drug Premium Pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUltragenyx prices orphan drugs at a premium to cover high R\u0026amp;D and manufacturing costs and tiny patient pools-many indications target fewer than 10,000 patients globally, with therapies often supported by per-patient annual prices exceeding $500,000 (e.g., recent rare disease drugs averaged $375k-$850k in 2024).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Assistance Programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUltragenyx runs patient assistance and co-pay programs that cap US out-of-pocket costs and provide grants; in 2024 the company reported aiding over 3,500 patients and covering an estimated $45M in patient expenses, lowering financial barriers for its high list-price rare-disease therapies. These programs boost adherence-studies show financial support can raise treatment persistence by ~15%-and protect corporate reputation amid pricing scrutiny.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Reference Pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eUltragenyx uses tiered international reference pricing, adjusting list prices to regional GDP and healthcare budgets-e.g., 2024 EMA market launches saw country-level discounts averaging 25-45% versus US list price to fit national formulary caps.\u003c\/p\u003e\n\u003cp\u003eThe company conducts tough negotiations with health authorities, securing reimbursed access while keeping target net price margins; 2023 global net price realization was ~62% of list price.\u003c\/p\u003e\n\u003cp\u003eCoordinated pricing and supply contracts reduce parallel trade and protect availability across markets, with country-specific price corridors and export controls to limit arbitrage.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAverage discount vs US: 25-45%\u003c\/li\u003e\n\u003cli\u003e2023 net price realization: ~62% of list\u003c\/li\u003e\n\u003cli\u003eUses price corridors and export clauses to prevent arbitrage\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReimbursement and Payer Negotiations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eUltragenyx works proactively with private insurers and government payers, including Medicare, to secure coverage pathways; by 2025 their market-access efforts focus on demonstrating value for rare-disease therapies priced in the high six-figures per patient annually.\u003c\/p\u003e\n\u003cp\u003eThey use detailed health economic and outcomes research (HEOR) to show cost-effectiveness-Ultragenyx submitted models showing QALY gains and budget-impact analyses in 2024-25 to support reimbursement.\u003c\/p\u003e\n\u003cp\u003eSecuring favorable formulary placement remains a primary objective for pricing and market-access teams, aiming for preferred placement on key specialty formularies and prior-authorization streamlining to limit patient access barriers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets: Medicare and major commercial plans\u003c\/li\u003e\n\u003cli\u003eEvidence: HEOR, QALY and budget-impact models (2024-25)\u003c\/li\u003e\n\u003cli\u003eGoal: Preferred formulary placement, prior-auth efficiency\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUltragenyx: $500K+ orphan drug pricing, ~62% net, €25-45% EU discounts, 3.5K patients aided\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUltragenyx uses value-based, premium pricing for orphan drugs (many indications \u0026lt;10,000 patients), with US list prices often \u0026gt;$500,000\/pt; 2023 net price realization ~62% and EU launches discounted 25-45%. Patient-assist programs helped \u0026gt;3,500 patients and covered ~$45M in 2024, improving adherence ~15% per HEOR-backed value cases (QALY, budget-impact 2024-25).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS list price\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$500,000\/pt\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet realization 2023\u003c\/td\u003e\n\u003ctd\u003e~62%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEU discount vs US\u003c\/td\u003e\n\u003ctd\u003e25-45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients aided 2024\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;3,500\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient aid paid\u003c\/td\u003e\n\u003ctd\u003e$45M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdherence lift\u003c\/td\u003e\n\u003ctd\u003e~15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"4P Marketing Mix","offers":[{"title":"Default Title","offer_id":64248204755293,"sku":"ultragenyx-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1058\/5151\/9325\/files\/ultragenyx-marketing-mix.webp?v=1776784296","url":"https:\/\/4pmarketingmix.com\/products\/ultragenyx-marketing-mix","provider":"4P Marketing Mix","version":"1.0","type":"link"}